Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Benign Prostatic Hyperplasia Patient is able and willing to comply with all the assessments of the study 2. Patient or patient's legal representative has been informed of the nature of the study, agrees to participate and has signed the informed consent form 3. ≥ 45 years of age 4. Baseline IPSS score > 13, and a baseline Quality of Life (QoL) question score > 3 5. Prostate volume 25 cc by Trans Rectal Ultrasound (TRUS) or abdominal ultrasound, measured within past 90 days and prostatic urethral length between 2.5 5 cm 6. Failed, intolerant, or patient choice to not take a medication regimen for the treatment of LUTS 7. Patient must meet ONE of the following 1. Baseline PSA <= 2.5ng/mL 2. Baseline PSA >2.5 ng/mL and <=10 ng/mL AND free PSA >=25% of total PSA (no biopsy required or negative biopsy) 3. Baseline PSA >10ng/mL AND negative prostate biopsy1 result within 12 months 4. Negative prostate biopsy1 within 12 months if abnormal digital rectal examination 5. 3 Tesla MRI of the prostate, with normal findings, within 12 months prior to the baseline visit  Obstructive intravesical median prostatic lobe which, in the opinion of the Investigator, would not benefit from treatment 2. Urethral stricture, meatal stenosis, or bladder neck obstruction either current, or recurrent requiring 2 or more dilations as reported in the patient's history 3. Requiring self-catheterization to void 4. Baseline PSA > 10 ng/mL or confirmed or suspected prostate cancer 5. Any of the following, taken from a single uroflowmetry reading: 1. Peak urinary flow rate > 12 ml/second 2. Post-void residual (PVR) > 250 ml 3. Peak Urinary flow rate of > 15 ml/second 4. < 125ml urinary volume voided at baseline (pre-bladder urinary volume of ≥ 150 ml required) 6. Other condition or disease that might cause urinary retention 7. History of other diseases causing voiding dysfunction 8. Concomitant Urinary Tract Infection (UTI) (subject can be enrolled following successful treatment of UTI and a clean urine test), or a history of recurrent or chronic UTIs (defined as 2 or more UTIs in the past 12 months) 9. Concomitant bladder stones 10. Previous pelvic irradiation or radical pelvic surgery 11. Previous prostate surgery, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate 12. Chronic prostatitis, or recurring prostatitis within the past 12 months 13. Known allergy to nickel 14. Life expectancy less than 24 months 15. Use of concomitant medications (e.g., anticholinergics, antispasmodics or antidepressants) affecting bladder function 16. Inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy not prohibited) 17. Taking 5-alpha reductase inhibitors within 3 months of pre-treatment (baseline) evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued throughout the study) 18. Taking one of the following within 2 weeks of pre-treatment (baseline) evaluation: 1. alpha-blockers, 2. androgens, 3. anticholinergics, or 4. cholinergic medication gonadotropin releasing hormonal analogs 19. Taking one of the following within 24 hours of pre-treatment (baseline) evaluation: 1. phenylephrine, or 2. pseudoephedrine 20. Future fertility concerns 21. Any severe illness that might prevent study completion or would confound study results